Watson, Apotex Settle Azilect Patent Infringement Suit

Law360, New York (May 23, 2013, 7:42 PM EDT) -- A New Jersey federal judge on Thursday dismissed Teva Pharmaceutical Industries Ltd.'s claims that generic-drug makers Watson Laboratories Inc. and Apotex Corp. infringed its patents for the Parkinson's disease drug Azilect, saying the parties have reached confidential settlement and licensing agreements.

U.S. District Judge Claire Cecchi signed off on two dismissal orders for Watson and Apotex to cap off Teva's patent infringement claims against the drugmakers aimed at blocking generic competition to Azilect before Teva's patent expires in 2017. Details on both confidential settlements were not...
To view the full article, register now.